Advanced search    

Search: authors:"Maiwenn J. Al"

6 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis

association of HAQ change by baseline DAS categories. (DOCX) Author Contributions Formal analysis: Evo Alemao. Methodology: Evo Alemao. Conceptualization: Evo Alemao, Maiwenn J. Al, Maureen P. M. H. Rutten ... -van MoÈlken. Supervision: Maiwenn J. Al, Maureen P. M. H. Rutten-van MoÈlken. Validation: Annelies A. Boonen, Matthew D. Stevenson, Suzanne M. M. Verstappen, Kaleb Michaud, Michael E. Weinblatt

Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal

. Conflict of interest Nasuh C. Bu¨ yu¨kkaramikli, Saskia de Groot, Debra Fayter, Robert Wolff, Nigel Armstrong, Lisa Stirk, Gill Worthy, Fernando Albuquerque de Almeida, Jos Kleijnen and Maiwenn J. Al have no

Mix and match. A simulation study on the impact of mixed-treatment comparison methods on health-economic outcomes

Background Decision-analytic cost-effectiveness (CE) models combine many parameters, often obtained after meta-analysis. Aim We compared different methods of mixed-treatment comparison (MTC) to combine transition and event probabilities derived from several trials, especially with respect to health-economic (HE) outcomes like (quality adjusted) life years and costs. Methods...

Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

contributed to the writing of the article. Rob Riemsma acted as project lead and systematic reviewer on this assessment, critiqued the clinical effectiveness methods and evidence. Maiwenn J. Al acted as health ... . Conflicts of interest Nasuh C. Bu¨yu¨kkaramikli, Hedwig M. Blommestein, Rob Riemsma, Nigel Armstrong, Fiona. J. Clay, Janine Ross, Gill Worthy, Johan Severens, Jos Kleijnen and Maiwenn J. Al have no conflicts

Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene

The National Institute for Health and Care Excellence (NICE) invited the manufacturer of lenalidomide (Celgene) to submit evidence of the clinical and cost effectiveness of the drug for treating adults with myelodysplastic syndromes (MDS) associated with deletion 5q cytogenetic abnormality, as part of the Institute’s single technology appraisal (STA) process. Kleijnen Systematic...

Cost-consequence analysis of remifentanil-based analgo-sedation vs. conventional analgesia and sedation for patients on mechanical ventilation in the Netherlands

Introduction Hospitals are increasingly forced to consider the economics of technology use. We estimated the incremental cost-consequences of remifentanil-based analgo-sedation (RS) vs. conventional analgesia and sedation (CS) in patients requiring mechanical ventilation (MV) in the intensive care unit (ICU), using a modelling approach. Methods A Markov model was developed to...